Research hotspots and trends in the field of immune checkpoint inhibitors (ICIs) for cervical cancer: A bibliometric study from 2014 to 2024.

IF 4.1 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-31 DOI:10.1080/21645515.2025.2483031

Chaoyan Shen, Juan Zhang, Guanyu Zhang, Hao Luo, Shuangke Zhang, Quan Yuan, Wei Xu, Wei Wang, Lele Miao

{"title":"Research hotspots and trends in the field of immune checkpoint inhibitors (ICIs) for cervical cancer: A bibliometric study from 2014 to 2024.","authors":"Chaoyan Shen, Juan Zhang, Guanyu Zhang, Hao Luo, Shuangke Zhang, Quan Yuan, Wei Xu, Wei Wang, Lele Miao","doi":"10.1080/21645515.2025.2483031","DOIUrl":null,"url":null,"abstract":"In recent years, immune checkpoint inhibitors (ICIs) have emerged as a novel immunotherapeutic approach, offering renewed hope for enhancing cervical cancer patient prognosis. This study represents the inaugural bibliometric analysis of ICIs in the context of cervical cancer, covering the period from 2014 to 2024. A total of 422 articles were identified through the Web of Science Core Collection database, amassing 10,977 citations, with a consistent annual increase in the number of publications. The leading contributors in terms of countries, institutions, journals, and authors included China, the University of Texas System, Frontiers in Oncology, and Bradley J. Monk, respectively. The journal with the highest frequency of citation and co-citation was Journal of Clinical Oncology. The researchers with the highest number of citations and co-citations were Sarina A Piha-Paul and Krishnansu S Tewari respectively. The keyword cluster analysis identified four main research directions. Furthermore, literature co-citation analysis and burst citation analysis revealed three research hotspots and four potential emerging topics within this domain, respectively. This study provides valuable reference and enlightenment for researchers in this field. As research progresses, ICIs are anticipated to offer significant hope and breakthroughs in the treatment of cervical cancer.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2483031"},"PeriodicalIF":4.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959921/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2483031","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, immune checkpoint inhibitors (ICIs) have emerged as a novel immunotherapeutic approach, offering renewed hope for enhancing cervical cancer patient prognosis. This study represents the inaugural bibliometric analysis of ICIs in the context of cervical cancer, covering the period from 2014 to 2024. A total of 422 articles were identified through the Web of Science Core Collection database, amassing 10,977 citations, with a consistent annual increase in the number of publications. The leading contributors in terms of countries, institutions, journals, and authors included China, the University of Texas System, Frontiers in Oncology, and Bradley J. Monk, respectively. The journal with the highest frequency of citation and co-citation was Journal of Clinical Oncology. The researchers with the highest number of citations and co-citations were Sarina A Piha-Paul and Krishnansu S Tewari respectively. The keyword cluster analysis identified four main research directions. Furthermore, literature co-citation analysis and burst citation analysis revealed three research hotspots and four potential emerging topics within this domain, respectively. This study provides valuable reference and enlightenment for researchers in this field. As research progresses, ICIs are anticipated to offer significant hope and breakthroughs in the treatment of cervical cancer.

查看原文本刊更多论文

2014 - 2024年宫颈癌免疫检查点抑制剂（ICIs）研究热点与趋势

近年来，免疫检查点抑制剂（ICIs）作为一种新型免疫治疗方法应运而生，为改善宫颈癌患者的预后带来了新的希望。本研究是首次对宫颈癌方面的 ICIs 进行文献计量分析，时间跨度为 2014 年至 2024 年。本研究通过科学网核心收藏数据库共检索到 422 篇文章，引用次数达 10,977 次，论文数量每年持续增长。在国家、机构、期刊和作者方面，主要贡献者分别包括中国、德克萨斯大学系统、《肿瘤学前沿》和 Bradley J. Monk。被引用和联合引用频率最高的期刊是《临床肿瘤学杂志》。被引用和联合引用次数最多的研究人员分别是 Sarina A Piha-Paul 和 Krishnansu S Tewari。关键词聚类分析确定了四个主要研究方向。此外，文献共引分析和突发引文分析分别揭示了该领域的三个研究热点和四个潜在的新兴课题。本研究为该领域的研究人员提供了宝贵的参考和启迪。随着研究的深入，ICIs有望为宫颈癌的治疗带来重大希望和突破。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

CiteScore

7.90

自引率

8.30%

发文量

489

审稿时长

3-6 weeks

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.